Abstract 103P
Background
The latest cancer statistics show that esophageal cancer ranks 9th in incidence and 6th in mortality among all cancers. Concurrent radiochemotherapy (CCRT) based on fluorouracil and platinum is one of the standard treatments for advanced stage patients. However, concurrent chemoradiotherapy will bring relatively serious toxic and side reactions. Studies have shown that about 40% of esophageal cancer patients are older than 70 years old, and most of these patients are more unable to tolerate CCRT. S-1, as an oral fluorouracil preparation, has achieved good clinical efficacy in the treatment of cancer with mild side effects. At present, some clinical studies have applied S-1 combined with synchronous radiotherapy in the treatment of elderly esophageal cancer. However, the sample size of these studies is small, and the results of some studies are different or even contradictory.
Methods
The Cochrane Library, Pubmed, Embase, CBM, CNKI, VIP and Wanfang database were searched. The Meta-analysis was performed by the Revman 5.3 software.
Results
A total of 1639 patients were enrolled in 23 studies. The results showed that, in terms of short-term efficacy, the combination therapy increased the incidence of CR[OR=2.12, 95%-CI (1.65, 2.73), P < 0.00001] and PR[OR=1.53, 95%-CI (1.23, 1.90).P =0.0002] and total response rate [OR=3.47, 95%ci (2,69,4.49), p < 0.00001].In terms of long-term efficacy, the combination therapy improved 1-year survival rate [OR=2.56, 95%CI (1.94, 3.38), P < 0.00001] and 2-year survival rate [OR=2.33, 95%CI (1.77, 3.08), P < 0.00001].In terms of side effects, the incidence of leucopenia, thrombocytopenia, radioactive esophagitis, nausea and vomiting in the combination therapy was higher than that in the control group (P < 0.05), but there was no significant difference in the incidence of anemia and radiation pneumonia (P > 0.05).
Conclusions
Available evidence suggests that S-1 combined with concurrent radiotherapy improves short-term therapeutic efficacy and survival time, but also increases the incidence of treatment-related side effects in older patients with esophageal cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
129P - Chemoradiation in carcinoma esophagus with weekly paclitaxel ad carboplatin: A real-world experience from a tertiary care center
Presenter: Nidhi Sharma
Session: Poster viewing 02
130P - Radiation induced lymphopenia (RAILs on time saves nine): In carcinoma esophagus
Presenter: Sheel Mohanty
Session: Poster viewing 02
131TiP - ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886
Presenter: Andrew Dean
Session: Poster viewing 02
134TiP - A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Presenter: Hiroshi Imaoka
Session: Poster viewing 02